image header

Investor Overview

Investor Overview

ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Our lead candidate, evorpacept (ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated proprietary Fc domain. We have developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities.

ALX Oncology

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

May 9, 2022

ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Read more

Apr 12, 2022

ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors Read more

Mar 2, 2022

ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer Read more